Abstract:Background Treating red blood cells (RBCs) with dithiothreitol (DTT) is a wildly-recommended to overcome the interference of anti-CD38 immunotherapy with blood compatibility testing. Nevertheless, DTT can be hard to obtain in clinical laboratory, while its use in routine practice may be time-consuming. In the following study, we explored the feasibility of using a commercial 2-mercaptoethanol (2-ME) working solution or the time-saving polybrene method to mitigate the daratumumab (DARA) interference. Materials and Methods Antibody screening and cross-matching were performed using 2-ME or DTT-based indirect antiglobulin tests (IATs) and polybrene method (human IgG anti-E same IATs titer as DARA as positive control) on 37 samples, and these samples were from patients enrolled in the “Several methods resolve the interference of anti-CD38 monoclonal antibody on blood compatibility tests” clinical trial ([www.chictr.org.cn][1] identifier: ChiCTR2000040761). Most clinically important blood group antigens on RBCs were detected after treatment with 2-ME or DTT. Hemoglobin values were compared after 69 units RBCs were transfused with compatible cross-matching results by a 2-ME-based method or polybrene test. Results Treating RBCs with 2-ME eliminates the DARA interference with the antibody screening or cross-matching; yet, K antigen is denatured during treatment. DARA with 2+ agglutinations of anti-E control does not interfere with antibody screening and cross-matching via polybrene method. After RBCs transfusion with a negative cross-matching test by 2-ME-based IATs or polybrene method, hemoglobin significantly increased without adverse transfusion reactions. Conclusion 2-ME-based IATs or polybrene method could be used to mitigate DARA interference as DTT. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial ChiCTR2000040761 (http://www.chictr.org.cn) ### Funding Statement This work was supported by WeiGao Science Foundation of Chinese Society of Blood Transfusion (CSBT-WG-2019-01), and National Natural Science Foundation of China (82000183). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was approved by all 5 ethics committees of the participated institutions; they are the ethics committee of Changzheng Hospital, the ethics committee of Shanghai Blood Center, the ethics committee of Ruijin Hospital, the ethics committee of Huashan Hospital, the ethics committee of Beijing Red Cross Blood Center. Written informed consent was obtained for each patient. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes The data used to support the findings of this study are available from the corresponding author upon request [1]: http://www.chictr.org.cn

How do transfusion services manage patients taking therapies such as anti‐CD38 and anti‐CD47 known to interfere with red blood cell compatibility testing?

Monoclonal anti‐CD47 interference in red cell and platelet testing

A Brief Report on Pre-Transfusion Testing in Patients Receiving the Anti-CD38 Monoclonal Antibody for Hematological Disorders in India

A MULTI-INSTITUTIONAL COLLABORATIVE STUDY OF PRETRANSFUSION TESTS IN PATIENTS WHO RECEIVED ANTI-CD38 THERAPY

Anti-CD38 monoclonal antibody interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping

Massive transfusion of incompatible red blood cells: A case report demonstrating the benefits of a regional patient alloantibody registry and prompt automated red cell exchange

Pretreatment with Daudi cells eliminates anti-CD47 monoclonal antibody interference in immunohematology testing

Review: Effects of anti-CD38 monoclonal antibodies on red blood cell transfusion and interventions

Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?

ELP protocol: an original approach for the mitigation of anti-CD38 interference

2-mercaptoethanol (2-ME)-based IATs or polybrene method mitigates the interference of anti-CD38 immunotherapy on blood compatibility tests

The role of daratumumab in complications post-allogeneic hematopoietic stem cell transplantation: a single-center prospective study on PRCA and AIHA

Daratumumab in the Management of Red Cell Aplasia Following Allogeneic Hematopoietic Stem Cell Transplantation

Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method

Transfusion‐induced Platelet Antibodies and Regulatory T Cells in Multiply Transfused Patients

ABO‐incompatible Living Kidney Transplantation

Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review

Abo-Incompatible Living Kidney Transplantation

Red blood cell alloimmunization in transfused patients with myelodysplastic syndromes: a retrospective study from northern China

Reliability of the pretransfusion bedside compatibility test: association with transfusion practice and training